Pfizer, a major player in the Streptomyces Derivatives Market, notably acquired Array BioPharma in July 2019. This merger brought advanced genetics and biotechnology capabilities to Pfizer, potentially enabling innovative applications of Streptomyces derivatives. Array BioPharma’s expertise in cancer research also provides new avenues for therapeutic applications of Streptomyces-derived antibiotics.
Syngenta launched an innovative Streptomyces-derived biofungicide to combat fungal diseases in crops. This development showcases the company’s commitment to leveraging Streptomyces derivatives for sustainable agriculture.
Scientists from MIT developed a novel technique to genetically engineer Streptomyces bacteria. This advancement is especially significant as it facilitates the discovery of new antibiotics, thereby playing a crucial role in the battle against antibiotic resistance.